← All trials
NCT00376766
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2007
- Primary completion
- Apr 1, 2008
- Completion date
- Apr 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 112
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- University of GrenobleLead sponsor
- La Teppe InstitutionOverall official - principal investigator
- Regional Hospital of ChamberyOverall official - principal investigator
- Jean Monnet UniversityOverall official - principal investigator
- University of StrasbourgOverall official - principal investigator
- University of LyonOverall official - principal investigator
- University of LilleOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- Hoosier Cancer Research NetworkCollaborator
- University of LorraineOverall official - principal investigator
- University Clermont AuvergneOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.